- Eleven Biotherapeutics has filed to raise up to $69M in an IPO on Nasdaq, where it will trade under the EBIO ticker symbol.
- Eleven Biotherapeutics develops a protein engineering platform called AMP-Rx for use in treating eye diseases.
- The company was founded in 2008 and earned $1M in collaboration revenue in the year through September.
- ETF: IPO
Eleven Biotherapeutics looks to raise almost $70M in IPO
Dec 31 2013, 07:28 ET